pISSN 1226-6051
eISSN 2508-786X

Table. 4.

Table. 4.

Detected signals of varenicline fulfilling the criteria for signal by three data mining indices including PRR, ROR and IC

No. PRR ROR χ2 IC IC 95% LCI AEs in drug label

MFDS* FDA*
Nausea 368 2.4 2.9 345.5 1.3 1.1 Y Y
Insomnia 117 7.2 7.7 627.2 2.9 2.6 Y Y
Dyspepsia 106 3.0 3.2 143.7 1.6 1.3 Y Y
Headache 69 2.3 2.4 51.6 1.2 0.9 Y Y
Dreaming abnormal 59 601.2 627.7 26877.8 8.9 8.4 Y Y
Depression 23 13.9 14.1 272.5 3.8 3.2 Y Y
Malaise 22 4.3 4.4 56.3 2.2 1.6 Y Y
Nightmares 21 109.0 110.7 2126.7 6.8 6.1 Y Y
Sleep disorder 21 22.1 22.4 418.4 4.5 3.9 Y Y
Hypotonia 20 21.8 22.1 392.0 4.5 3.9 N N
Appetite increased 11 11.4 11.5 103.5 3.6 2.8 Y Y
Weight increase 10 3.4 3.4 17.1 1.9 1.0 Y Y
Anxiety 8 2.3 2.3 6.0 1.4 0.4 Y Y
Amnesia 6 10.0 10.1 48.6 3.5 2.4 Y Y
Incorrect dose administered 5 20.3 20.3 90.7 4.6 3.4 N N
Mood swings 4 23.3 23.4 84.4 4.8 3.5 Y Y
Aggressive reaction 3 12.4 12.4 31.1 4.0 2.6 Y Y
Suicide attempt 3 12.1 12.1 30.4 4.0 2.6 Y Y

*PRR, Proportional Reporting Ratio; ROR, Reporting Odds Ratio; χ2, chi-squared; IC 95% LCI, Information Component lower limit of 95% confidence interval; AEs, Adverse Events; MFDS, Ministry of Food and Drug Safety; FDA, Food and Drug Administration.

Korean J Clin Pharm 2022;32:1-7 https://doi.org/10.24304/kjcp.2022.32.1.1
© 2022 Korean J Clin Pharm